Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arrowhead Pharmaceuticals reports strong Q1 earnings and outlines growth strategy

Arrowhead Pharmaceuticals showcased solid financial performance, promising clinical outcomes, and a strategic growth plan during the Q1 2023 earnings call.
While facing challenges in financial losses and program complexities, the company's strengths in innovation, partnerships, and pipeline development position them for future success.
Opportunities lie in upcoming data releases, therapeutic advancements, and strategic collaborations, offering avenues for market expansion and medical breakthroughs.
Overall, Arrowhead Pharmaceuticals demonstrates resilience, innovation, and a clear vision for growth in the competitive biopharmaceutical landscape.

Arrowhead Pharmaceuticals reports robust Q2 earnings and expands pipeline

Arrowhead Pharmaceuticals delivered strong financial results and showcased progress in its drug pipeline, particularly in the pulmonary and CNS spaces.
While facing challenges in translating preclinical success to clinical outcomes and navigating competitive landscapes, the company's strategic partnerships and efficient cost management are key strengths.
Opportunities lie in expanding into new therapeutic areas, leveraging external interest for internal development, and benefiting from regulatory insights in the CNS field.
Overall, Arrowhead Pharmaceuticals remains well-positioned for future growth and innovation in the biopharmaceutical sector.

Arrowhead Pharmaceuticals advances pipeline with strong financial backing

Arrowhead Pharmaceuticals made progress in de-risking its pulmonary franchise and advancing key cardiometabolic candidates.
The company's strong financial position and focus on partnerships support its goal of expanding the pipeline to 20 products by 2025.
Challenges include high operating expenses, the need for specific financing for trials, and managing cash burn effectively.
Exploration of CNS targets and upcoming Phase 2 data presentations offer growth opportunities for Arrowhead Pharmaceuticals.

Arrowhead Pharmaceuticals advances key products towards commercialization amid financial challenges

Arrowhead Pharmaceuticals made significant progress on key products and is advancing towards commercialization and de-risking their pipeline.
Despite facing a net loss, the company remains focused on expanding their product portfolio and exploring new treatment options.
Strategic partnerships and ongoing research efforts position Arrowhead well for future growth and potential commercial success.
Managing financial challenges and optimizing trial strategies will be crucial for Arrowhead's continued success in the biopharmaceutical industry.

Arrowhead Pharmaceuticals advances RNAi pipeline with cardiometabolic focus

Arrowhead Pharmaceuticals focuses on advancing RNAi therapeutics with a cardiometabolic emphasis.
Financials show a net loss with plans to strengthen the balance sheet and decrease operating expenses.
Exploring debt financing, partnerships, and new innovations for pipeline expansion and commercial growth.
Challenges include data delays, uncertain timelines, and the need for additional biomarker data.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals to present at August 2020 conferences

Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma

Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma

BioBoyScout recently raised his price target on Arrowhead Pharmaceuticals to $107.

Arrowhead Pharmaceuticals Could Be A Quick And Easy Double Up From Here

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis

Most Medical Development & Treatment companies tend not to be involved in the Covid-19 virus vaccine race.

Arrowhead Pharmaceuticals: Now The Best Biotech Stock With Near-Term Capital Gain Prospects

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q3 2020 Results - Earnings Call Transcript

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals reports fiscal Q3 2020 earnings results and hosts conference call

Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA

Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals and Marcus Mall MD host a webinar on ARO-ENaC for the treatment of cystic fibrosis

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis

Arrowhead Pharmaceuticals: Updates To Thesis, RNAi Pioneer Continues To Move Key Programs Closer To Inflection Points

The RNAi treatment developer is clawing its way back after a rough start to 2020.

Here's Why Arrowhead Pharmaceuticals Stock Jumped 34% in June

Arrowhead Pharmaceuticals Is A Long-Term Investment To Consider

Quietly Adding More Shares Of Arrowhead Pharmaceuticals

Johnson & Johnson

Will the pharma giant be interested in acquiring a mid-cap partner with a promising treatment for hepatitis B?

Will Johnson & Johnson Acquire Arrowhead Pharmaceuticals?

The development-stage genetic medicine company is eager to convert its intriguing potential into tangible progress.

Is Arrowhead Pharmaceuticals a Buy?

A leading company in the field of gene silencing is on track to develop several breakthrough therapies.

Will Arrowhead Pharmaceuticals Be a Biotech Winner?

Arrowhead Pharmaceuticals, Inc. (ARWR) CEO Christopher Anzalone on Q2 2020 Results - Earnings Call Transcript

The collaboration between a pharmaceutical giant and a mid-cap biotech company may have accomplished the impossible.

Is Arrowhead Pharmaceuticals Close to a Cure for HBV?

Arrowhead Pharma shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 71 to 84.
The post Stocks To Watch: Arrowhead Pharma Sees Relative Strength Rating Jump To 84 appeared first on Investor's Business Daily.

Stocks To Watch: Arrowhead Pharma Sees Relative Strength Rating Jump To 84

Arrowhead Pharmaceuticals Long-Term Intact As Shorts Finish Taking Profits

After a stellar 2019, the biotech stock has lost 47% so far in 2020.

Why Arrowhead Pharmaceuticals Shares Dropped 15% in February

Arrowhead Pharmaceuticals: Greed Vs. Fear

Arrowhead Pharmaceuticals: Why JNJ-3989 May Become A First-Line Therapy For Chronic HBV

Investors began to question the excessive market valuation for the early-stage biopharma, but the company still has plenty of potential.

Here's Why Arrowhead Pharmaceuticals Fell 33.9% in January

The clinical-stage biotech posted a revenue decline and a widening net loss in Q1. But no one cared.

News for Arrowhead Pharmaceuticals Stock (ARWR)